News & Opinions Home
Market Place
Busiwire
Research and Markets: This Essential Opportunities Assessment Report for Diabetes Therapeutics in South Korea is Now Available
Friday May 15, 04:17 AM
Research and Markets (http://www.researchandmarkets.com/research/cac749/opportunities_asse)
has announced the addition of Frost & Sullivan's new report "Opportunities
Assessment for Diabetes Therapeutics: South Korea" to their offering.
This research service aims to provide an update on the epidemiology of
T2 diabetes, current diagnostic and treatment practices, as well as
market landscape in terms of major participants and future trends. It
covers the diabetes therapeutics market in South Korea.
Research Overview
This Frost & Sullivan research service titled Opportunities
Assessment for Diabetes Therapeutics: South Korea provides an
overview on the epidemiology of type 2 diabetes in South Korea. Details
are provided for current and forecasted prevalence and incidence of
diabetes, government initiatives to support persons with diabetes as
well as current diagnostic and treatment practices. The treatment of
type 2 diabetes forms a key part of each report and covers patient flow,
treatment options used, and future trends in the treatment of the
disease.
This analysis is available through our Pharmaceutical and Biotechnology
Growth Partnership Services program. With continuous access to
intelligence and resources from all seven perspectives of the Complex
Business Universe, the Growth Partnership Services program ensures that
you and your Growth Team are able to maintain a 360 Degree Perspective
of the market. This comprehensive, objective information allows your
company to mitigate risk, identify new opportunities, and drive
effective strategies for growth. For more information on this custom
subscription service, please click here.
Market Overview
Oral Antidiabetic Drugs Displace Conventional Drugs in South Korean
Diabetes Therapeutics Markets
The incidence of diabetes is on the rise in South Korea and estimates
reveal that South Korea's diabetic population will touch 3.7 million by
2012. Type 2 diabetes mellitus is a major health problem worldwide with
high morbidity and mortality rates, incurring substantial healthcare
costs. The prevalence of this disorder is expected to double over the
next 25 years globally. In South Korea, volumes on each therapy will
grow and type 2 diabetes patients on oral combination therapy and oral
monotherapy are expected to increase. The use of insulin will witness a
steady decline, due largely to factors such as earlier detection of the
disease, better control in the early stages, and the availability of an
ever-expanding array of oral antidiabetics, which are preferable options
to insulin treatment.
Considering the large number of active domestic participants that
manufacture generics in the diabetes therapeutics space, fierce
competition between multinational companies and domestic pharmaceutical
companies will ensue, changing the market extensively. "New drugs will
be continuously developed to meet patient requirements and although the
gold standard in diabetes treatment is still the traditional treatment,
there is unmet need in terms of long-term efficacy," notes the analyst
of this research service. "There is a need to fully evaluate opportunity
for target agents and understand evolving market dynamics
class-by-class." Participants must assess the latent opportunities in
the market and launch strategic planning initiatives to meet market
needs.
"Currently, Metformin and Sulfonylurea are the most used oral
antidiabetic drugs (OAD) in the treatment of diabetes in South Korea,"
explains the analyst. "While they will continue to remain the mainstay
of treatment, in the future, innovative drugs - mainly DPP-IV and GLP-1
- are expected to partially replace the current Metformin, Sulfonylurea,
and TZD markets." Several OADs are in the pipeline, among them DPP-IV
inhibitor and GLP-1 offer the greatest potential from both the angles of
efficiency and acceptability. A prominent advantage which provides the
edge for DPP-IV inhibitors is ease of administration, while GLP-1
promises additional benefits such as weight loss and stronger efficacy
in terms of HbA1c reduction.
Government support for diabetes is limited compared to other diseases
such as cancer. Estimates reveal that while $120 million is spent on
cancer, only $2.5 million is spent on diabetes. More active
participation is required on the part of the government to support
diabetes prevention and treatment. There is a distinct lack of public
education on diabetes and only a few small groups operate at some of the
general hospitals. There is a pressing need to spread awareness of the
disease, its treatment and management, and lifetime implications. Public
campaigns must be undertaken by both the government and pharmaceutical
companies to ratchet up awareness levels on the seriousness of diabetes.
Key Topics Covered:
OPPORTUNITIES ASSESSMENT FOR DIABETES THERAPEUTICS , EXECUTIVE SUMMARY
Overview
Market Trends
Growth Segments
Growth Opportunities
OPPORTUNITIES ASSESSMENT FOR DIABETES THERAPEUTICS , DIABETES
THERAPEUTICS MARKET
Market Overview
Introduction
Context for the Study
Research Scope and Segmentation
Methodology
Restraints in Forecasts
OPPORTUNITIES ASSESSMENT FOR DIABETES THERAPEUTICS , SOUTH KOREAN
DIABETES THERAPEUTICS MARKET
Market Overview
Introduction
Market Engineering Measurements
Market Forecasts and Trends
Patient Forecast -- Cost of Treatment
Treatment and Diagnosis
Key Treaters and Patient Flow
Diagnostic Tests
Treatment Options
Key Factors/Drivers to Prescribe Insulin
Product/Class Launches in 2007/2008 and in Future
Clinical Trials
Competitive Analysis
Competitive Structure
Market Share Analysis
Future Trends
Challenges Faced by Physicians
OPPORTUNITIES ASSESSMENT FOR DIABETES THERAPEUTICS , APPENDIX
South Korea
For more information visit http://www.researchandmarkets.com/research/cac749/opportunities_asse
Contact:Research and MarketsLaura WoodSenior Managerpress@researchandmarkets.comFax
from USA: 646-607-1907Fax from rest of the world: +353-1-481-1716
Next Article: Research and Markets: Get Updated Facts and Figures on the Evolution of the National Energy Market with This Essential South Korea Energy Report
Previous article: Research and Markets: South Korean Payment Card Market - Available Now
Top Headlines
Research and Markets: Opportunities Assessment for Diabetes Therapeutics - Australia
Saturday May 16, 02:00 AM - Busiwire
Research and Markets (http://www.researchandmarkets.com/research/7ebbc2/opportunities_asse) has announced the addition .. Read More
Mt Isa Metals Limited (ASX:MET) Announces Significant Results From RC Drilling At The D-Tree Phosphate Project
Friday May 15, 08:19 PM - Asia Business News
Brisbane, Australia, May 15, 2009 - (ABN Newswire) - Mt Isa Metals Limited (ASX:MET) is pleased to announce that further sig .. Read More
NZ sharemarket finishes week firm
Friday May 15, 06:26 PM - NZPA
The New Zealand sharemarket put some runs on the board today and among the best performers was Sir Ron Brierley's Guinness Pe .. Read More
Calculators
Copyright © 2009 Yahoo! All rights reserved.
Yahoo!Xtra: A Yahoo!7/Telecom New Zealand Company.